Abuse Potential Clinical Trial
Official title:
A Randomized, Double-Blind, 6-Way Crossover Study to Determine the Abuse Potential of Tozadenant Relative to D-Amphetamine and Placebo When Administered Orally in Healthy, Non-Dependent, Recreational Polydrug Users With Stimulant Experience, Under Fed Conditions
This will be a single-dose, randomized, double-blind, active- and placebo-controlled, double
dummy, 6-way crossover study to determine the abuse potential of tozadenant relative to
d-amphetamine and placebo, when administered orally in healthy non-dependent, recreational
polydrug users with stimulant experience, under fed conditions.
Each subject will participate in a medical Screening visit, a 4-day (3-night) qualification
(drug discrimination) visit, six 3-day (2-night) treatment periods, and a follow-up visit.
The Qualification Phase will be conducted as a single, 4-day visit. Doses will be
administered in a randomized, double-blind crossover manner following administration of a
standard low-fat meal. Subjects will be dosed with 20 mg of d-amphetamine or matching placebo
d-amphetamine on Day 1 and Day 2, approximately 24 hours apart. PD assessments will be
conducted before dosing and at time points for up to 8 hours post dosing. Safety assessments
will be conducted before dosing and for at least 24 hours following dosing. Data will be
reviewed to determine subject eligibility.
The last drug administration in the Qualification Phase and the first drug administration in
the Treatment Phase will be separated by a washout interval of at least 7 days and not to
exceed 28 days.
During the Treatment Phase, there will be 6 treatment periods; subjects will receive a single
oral dose of each of the following treatments with applicable matching oral placebos in a
randomized, double-blind, double-dummy fashion following the administration of a standard,
low-fat meal. The following treatments will be administered:
- Treatment A: placebo (matched to tozadenant and d-amphetamine)
- Treatment B: tozadenant 120 mg
- Treatment C: tozadenant 240 mg
- Treatment D: tozadenant 480 mg
- Treatment E: d-amphetamine 20 mg
- Treatment F: d-amphetamine 40 mg
Drug administration will occur on Day 1 of each of the 6 treatment periods. PD and PK
assessments will be collected during the 24 hours post-dose and safety assessments will be
collected during the 36 hours post-dose. Subjects will be discharged on Day 2, after
approximately 36 hours post-dose, or remain at the clinical research unit longer (e.g., 48
hours or until the following morning) if there are safety concerns, at the discretion of the
investigator or designee. Drug administration in each treatment period will be separated by a
washout interval of at least 7 days after the last dose of study drug.
Subjects will return for an end-of-study safety Follow-up visit approximately 7 to 14 days
after the subject's last study drug dose in the Treatment Phase or following early
withdrawal.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT06097676 -
An Abuse Potential Study of Orally Administered HORIZANT in Healthy, Non-dependent, Recreational Drug Users
|
Phase 4 | |
| Completed |
NCT04570436 -
Evaluating the Abuse Potential of NEURONTIN® When Taken Orally in Healthy Non-drug Dependent Participants With Sedative Drug Abuse Experience
|
Phase 4 | |
| Completed |
NCT05053126 -
Study Evaluating Abuse Potential of Lyrica® in Healthy Non-Drug Dependent Recreational Opioid Users
|
Phase 4 | |
| Completed |
NCT06247488 -
Evaluation of Abuse Potential of HORIZANT Taken Alone and With Oxycodone in Healthy, Nondependent Recreational Opioid Users
|
Phase 4 | |
| Completed |
NCT05106153 -
A Study to Determine the Abuse Potential of Seltorexant Compared to Suvorexant and Zolpidem
|
Phase 1 | |
| Completed |
NCT05319756 -
Study Evaluating the Abuse Potential of NEURONTIN® in Healthy Non-drug Dependent, Recreational Opioid Users
|
Phase 4 |